公开(公告)号：US20220332804A1

公开(公告)日：2022-10-20

申请号：US17634606

申请日：2020-08-12

申请人： CSL Innovation Pty Ltd.

发明人： Matthew Hardy ,  Con Panousis ,  Rodrigo Morales

IPC分类号： C07K16/18

摘要： The present disclosure relates to proteins comprising antigen binding sites that bind to human complement C2 (C2). The present disclosure also relates to methods of inhibiting complement activity in a subject as well as methods of treating or preventing complement-mediated disorders.

公开(公告)号：US20210269517A1

公开(公告)日：2021-09-02

申请号：US17276611

申请日：2019-09-18

申请人： CSL Limited ,  CSL Innovation Pty Ltd ,  B-Creative Sweden AB

发明人： Ulf ERIKSSON ,  Annelie FALKEVALL ,  Annika MEHLEM ,  Isolde PALOMBO ,  Samuel WRIGHT

IPC分类号： C07K16/22 ,  C12N15/113 ,  A61P3/00

摘要： The present disclosure provides a method of treating a wasting disorder in a subject, the method comprising administering to the subject a compound that inhibits VEGF-B signalling. The present disclosure also provides a method of treating cancer cachexia in a subject suffering from cancer cachexia, the method comprising 5 administering to the subject a compound that inhibits VEGF-B signaling.

公开(公告)号：US20220220209A1

公开(公告)日：2022-07-14

申请号：US17299590

申请日：2019-12-04

申请人： CSL Innovation Pty Ltd

发明人： Karen Lisa INGUANTI ,  Jolanta AIREY ,  Jagdev SIDHU ,  Michael TORTORICI ,  Theresa YURASZECK

IPC分类号： C07K16/28 ,  A61P17/10 ,  A61P17/06

摘要： The present disclosure relates to a method for reducing circulating neutrophils in a subject without causing sustained grade 3 or grade 4 neutropenia. The present disclosure also relates to methods for treating neutrophilic conditions with an antibody that inhibit G-CSF signalling. In particular, the present disclosure relates to methods of 5 treating neutrophilic dermatoses, such as hidradenitis suppurativa (HS) and palmoplantar pustulosis (PPP).

公开(公告)号：US20230002508A1

公开(公告)日：2023-01-05

申请号：US17781995

申请日：2020-12-03

申请人： CSL INNOVATION PTY LTD

发明人： lngo PRAGST ,  Dipti PAWASKAR ,  Theresa YURASZECK ,  Ying ZHANG

IPC分类号： C07K16/36 ,  A61P7/00

摘要： The present disclosure relates to methods of treating or preventing hereditary angioedema (HAE) in a subject in need thereof by subcutaneously administering to the subject an effective amount an anti-FXII antibody comprising (i) a VH comprising a CDRH1 comprising a sequence set forth in SEQ ID NO:1; a CDRH2 comprising a sequence set forth in SEQ ID NO:2; and a CDRH3 comprising a sequence set forth in SEQ ID NO:3; and (ii) a VL comprising a CDRL1 comprising a sequence set forth in SEQ ID NO:4; a CDRL2 comprising a sequence set forth in SEQ ID NO:5; and a CDRL3 comprising a sequence set forth in SEQ ID NO:6.

公开(公告)号：US20220305133A1

公开(公告)日：2022-09-29

申请号：US17618076

申请日：2020-06-12

申请人： CSL Innovation Pty., Ltd.

发明人： Matthew Hardy

IPC分类号： A61K47/68 ,  A61P7/02

摘要： A soluble complement receptor type 1 (sCR1) conjugate comprising a sCR1 variant and a) a protein comprising an antigen binding domain that binds to a target and inhibits signaling by or via the target; orb) a protein comprising an antigen binding domain that binds to a blood coagulation factor.

公开(公告)号：US20220273713A1

公开(公告)日：2022-09-01

申请号：US17622563

申请日：2020-06-26

申请人： The University of Melbourne ,  Olivia Newton-John Cancer Research Institute ,  CSL INNOVATION PTY LTD

发明人： Andreas BEHREN ,  Jonathan CEBON ,  Marc Rigau CORTAL ,  Thomas Samuel FULFORD ,  Dale Ian GODFREY ,  Andrew HAMMET ,  Simone OSTROUSKA ,  Con PANOUSIS ,  Adam Peter ULDRICH

IPC分类号： A61K35/17 ,  C07K16/28 ,  C07K14/725 ,  A61P31/00 ,  A61P35/00 ,  A61P37/00

摘要： The present disclosure relates to methods for inhibiting activation of γδ T cells that express a Vγ9+ TCR in a subject by administering a BTN2A1 antagonist to a subject as well as methods for inducing or enhancing γδ T cells that express a Vγ9+ TCR in a subject by administering a BTN2A1 antagonist to a subject. The disclosure additionally relates to BTN2A1 antagonists and BTN2A1 agonists.